Donate

Research

The future has never been more hopeful

It is a particularly exciting time for Huntington’s research. Countless doctors and scientists around the world are actively involved in research projects and clinical trials in the field of neurology in general and Huntington’s Disease in particular.

Find the latest research news in the following sources:

Clinical Trials

DIMENSION

Status: Active and recruiting

Aims and goal: The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.

Location: United States of America, Australia, Canada and United Kingdom

Learn more

KINECT-HD2

Status: Enrollment closed

Aims and goal: KINECT-HD2 is an Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntington’s Disease.

Location: United States of America and Canada

Learn more

Phase I/II Clinical Trial of AMT-130

Status: Recruiting

Aims and goal: This is the first study testing AMT-130 in humans. The main purpose is to find a safe dose of AMT-130 in adults who have tested positive for the HD gene and who have early-stage HD. The study will also look at how the body processes AMT-130 and will explore how it might affect how the disease progresses.

Location: Germany, Poland and United Kingdom

Learn more

GENERATION HD2

Status: Recruiting

Aims and goal: This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington’s Disease

Location: Argentina, Australia, Austria, Canada, Denmark, France, Germany, Italy, New Zealand, Poland, Portugal, Spain, Switzerland, United Kingdom, United States of America

Learn more

SOM3355 for Huntington’s disease

Status: Completed

Aims and goal: SOM3355 has successfully completed a Phase 2a trials in HD and shown a favorable safety profile with no neurological or neuropsychiatric side effects. The Phase 2b dose-range finding trial program received guidance from Pre-IND discussions with the US Food and Drug Administration (FDA) and Scientific Advice from the European Medicines Agency (EMA). 

Location: France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom

Learn more

PIVOT-HD

Status: Active

Aims and goal: The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.

Location: Australia, Austria, Canada, France, Germany, Italy, Netherlands, New Zealand, Spain, United Kingdom

Learn more

SELECT-HD

Status: Completed

Aims and goal: The SELECT-HD trial was a global, multicenter, randomized, double-blind, placebo-controlled Phase 1b/2a clinical trial to assess the safety and tolerability of single- and multiple-ascending intrathecal doses of WVE-003 in people with a confirmed diagnosis of HD who are in the early stages of the disease and carry SNP3 in association with their cytosine-adenine-guanine (CAG) expansion. Additional objectives include assessing pharmacokinetics and exploratory pharmacodynamic and clinical endpoints. 

Location: Australia, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom

Learn more

PROOF-HD

Status: Completed – waiting for pridopidine approval

Aims and goal: PROOF-HD is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of pridopidine in patients with early stage of Huntington disease.

Learn more

Research Updates
News

Novartis Announces INVEST-HD

Novartis development of Votoplam in HD: INVEST-HD Phase 3 trial information now available February 3rd 2026 Dear Huntington’s disease Community, We are delighted to share an update on

Read More
February 10, 2026

Ongoing clinical trial updates from EHDN & Enroll-HD 2024 Strasbourg